ArQule CFO resigns to join Incyte

NEW YORK (CBS.MW) -- David Hastings has resigned as chief financial officer of drug discovery firm ArQule
ARQL, +2.67%
effective Oct. 6, to accept the same position with Incyte Corp.
INCY, -4.19%
starting on Oct. 14. Hastings had joined ArQule as CFO and treasurer in 2000, and had previously worked at Genzyme, Sepracor and PriceWaterhouseCoopers. ArQule shares closed Tuesday up 46 cents at $4.60 and Incyte slipped 16 cents to $4.63.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.